

# Child & Adolescent Psychiatry Grand Rounds

## WCM Department of Psychiatry

Psychology CE Announcement

### *“Efficacy and Safety of Antipsychotics in Youth with Severe Mental Illness”*

## Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, New York, USA and  
Professor of Child and Adolescent Psychiatry at Charité – University Medicine, Berlin, Germany

Wednesday, December 14<sup>th</sup>, 2022

11:00am – 12:30pm

<https://weillcornell.zoom.us/j/92812036154>

Meeting ID: 928 1203 6154

Password: 12345

\*1.5 CE credit available to full time and voluntary faculty psychologists and Social Workers who sign in with their full name, attend the majority of the lecture and complete a survey which will be emailed following the completion of the lecture.

#### SPEAKER DISCLOSURE:

Dr. Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viartis. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantia. Dr. Correll DOES NOT INTEND to discuss off-label or investigational use of products or services.

Dr. Christoph U. Correll is Professor of Psychiatry at The Zucker School of Medicine at Hofstra/Northwell, New York, USA, and also Professor and Chair of the Department of Child and Adolescent Psychiatry, Charité University Medicine, Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board-certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City. Since 1997, he has been working and conducting research in New York, USA, and since 2017 he is also working in Germany again

**Abstract:** About one third of mental disorders are diagnosed before age 14 and about half before age 18. Early-onset psychiatric disorders are often associated with severe symptomatology and functional impairment and require pharmacologic treatment in addition to psychosocial interventions. Antipsychotic agents are indicated for several severe psychiatric disorders and are used off-label for even more. This presentation will review the randomized controlled efficacy and safety evidence supported by safety data from naturalistic studies. Data will put into a clinical context to enhance clinical decision making in this vulnerable patient group with regards to treatment selection as well as adequate monitoring strategies.

#### Learning Objectives:

1. Describe the controlled efficacy data for antipsychotics compared to placebo and compared to each other in pediatric psychotic disorders, bipolar disorder, Tourette and aggressive spectrum disorders
2. Recognize the frequency and magnitude of clinically relevant adverse effect clusters associated with specific antipsychotics during development
3. Select antipsychotic treatment in youths considering the available tolerability and efficacy information, as well as pharmacological properties
4. Implement appropriate monitoring and management strategies to minimize antipsychotic-induced adverse events.

#### References:

1. Correll CU, Cortese S, Croatto G, Monaco F, Krnitski D, Arrondo G, Ostinelli EG, Zangani C, Fornaro M, Estradé A, Fusar-Poli P, Carvalho AF, Solmi M. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. *World Psychiatry*. 2021 Jun;20(2):244-275. doi: 10.1002/wps.20881. PMID: 34002501; PMCID: PMC8129843.
2. Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krnitski D, Fusar-Poli P, Correll CU. Safety of 80 antidepressants, antipsychotics, antiattention- deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. *World Psychiatry*. 2020 Jun;19(2):214-232.
3. Pagsberg AK, Tarp S, Glinthorpe D, Stenstrom AD, Fink-Jensen A, Correll CU, Christensen R. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis. *J Am Acad Child Adolesc Psychiatry*. 2017 Mar;56(3):191-202. doi: 10.1016/j.jaac.2016.12.013. Epub 2016 Dec 29. PMID: 28219485.
4. Scotto Rosato N, Correll CU, Pappadopulos E, Chait A, Crystal S, Jensen PS; Treatment of Maladaptive Aggressive in Youth Steering Committee. Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. *Pediatrics*. 2012 Jun;129(6):e1577-86. doi: 10.1542/peds.2010-1361. Epub 2012 May 28. PMID: 22641763.
5. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. *Bipolar Disord*. 2010 Mar.